Progyny (PGNY) Competitors

Guardant Health (NASDAQ:GH) and Progyny (NASDAQ:PGNY) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, community ranking, risk, analyst recommendations, earnings, dividends and profitability.

Do analysts recommend GH or PGNY?

Guardant Health presently has a consensus price target of $48.95, indicating a potential upside of 5.32%. Progyny has a consensus price target of $24.82, indicating a potential upside of 12.71%. Given Progyny's higher probable upside, analysts clearly believe Progyny is more favorable than Guardant Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guardant Health	0 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	3.00
Progyny	0 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.31

Which has stronger valuation & earnings, GH or PGNY?

Progyny has higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guardant Health	$739.02M	7.76	-$479.45M	-$3.56	-13.06
Progyny	$1.17B	1.61	$62.04M	$0.57	38.63

Is GH or PGNY more profitable?

Progyny has a net margin of 5.03% compared to Guardant Health's net margin of -59.05%. Progyny's return on equity of 11.36% beat Guardant Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Guardant Health	-59.05%	-19,157.20%	-25.96%
Progyny	5.03%	11.36%	7.87%

Which has more risk and volatility, GH or PGNY?

Guardant Health has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Progyny has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.

Does the MarketBeat Community believe in GH or PGNY?

Guardant Health received 193 more outperform votes than Progyny when rated by MarketBeat users. Likewise, 71.01% of users gave Guardant Health an outperform vote while only 70.63% of users gave Progyny an outperform vote.

Company	Underperform	Outperform
Guardant Health	Outperform Votes 294 71.01%	Underperform Votes 120 28.99%
Progyny	Outperform Votes 101 70.63%	Underperform Votes 42 29.37%

Do institutionals and insiders believe in GH or PGNY?

92.6% of Guardant Health shares are owned by institutional investors. Comparatively, 94.9% of Progyny shares are owned by institutional investors. 5.5% of Guardant Health shares are owned by company insiders. Comparatively, 12.3% of Progyny shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Does the media refer more to GH or PGNY?

In the previous week, Guardant Health had 9 more articles in the media than Progyny. MarketBeat recorded 15 mentions for Guardant Health and 6 mentions for Progyny. Progyny's average media sentiment score of 1.63 beat Guardant Health's score of 0.85 indicating that Progyny is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Guardant Health	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Progyny	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Progyny beats Guardant Health on 11 of the 18 factors compared between the two stocks.